Core Viewpoint - The company, He Bo Pharmaceutical-B (02142.HK), has announced a placement agreement with Citibank to issue 45.022 million shares at a price of HKD 11.50 per share, which represents approximately 5.45% of the existing issued share capital [1] Group 1 - The placement shares will account for approximately 5.17% of the enlarged issued share capital post-placement, assuming full subscription and no changes in the issued share capital from the announcement date to completion [1] - The estimated total gross proceeds from the placement are approximately HKD 517.8 million, with net proceeds expected to be around HKD 511.7 million after deducting placement commissions and other related expenses [1] Group 2 - The net proceeds from the placement will be allocated as follows: approximately 50% for the development of innovative drug assets, about 40% for advancing clinical trials of existing pipeline drug assets, and around 10% for working capital and other general corporate purposes [1]
和铂医药-B(02142.HK)拟配股总筹5.18亿港元 加速创新药研发及临床试验